Biotech Scan

Scan

Biotech Scan

Scan symbols 15
XBIBEAMLEGNMRNAKYMRPTGXNTLAALNYREGNGILDISRGNKTRSRPTNVOBNTX
Watchlists 1
@biotech-scan
raw scan snapshot — prices as of scan date, not live 50 rows · screens, not recommendations

Gene-editing + mRNA cohort leading a broad biotech risk-on melt-up: XBI breakout (RSI 62, near ATH), BEAM (+29.7% 30D), MRNA (+15.2% 30D), LEGN (+80% 3M) all golden-crossed and strong-up — while large-cap antibody/rare-disease names (REGN, ALNY, ISRG, NVO) stay in death-cross collapse. Risk appetite is rotating into small/mid-cap platform biotech, not the legacy majors.

Source: biotech-scan.json. Latest bar Thursday 2026-06-18; some names 06-16 (2d stale) flagged inline.

Quick Snapshot

Signal Reading
Overall 🟢 Risk-on across small/mid biotech — XBI broke out (RSI 62, -2.8% from ATH, +15% 3M); gene-editing (BEAM/NTLA/CRSP) and mRNA (MRNA) ripping; ETFs (XBI/IBB/IBBQ) all golden-crossed and strong-up
Leaders LEGN (+80% 3M, RSI 57), BEAM (+29.7% 30D, RSI 62), KYMR (+15.7% 7D, RSI 63), MRNA (+15.2% 30D, RSI 64), PTGX (+13.6% 7D, RSI 61, -2.7% from ATH)
Laggards NKTR (RSI 37↓, -19.7% 3M, collapse), REGN (RSI 39, -18.9% 3M, death-cross), GILD (RSI 40, -11.7% 3M), SRPT (RSI 40, -37.7% from ATH), ALNY (RSI 42, -43.9% from ATH, collapse)
Key insight The whole ETF complex (XBI/IBB/IBBQ/LABU) is golden-crossed and near ATH while individual large-caps (REGN/ALNY/NVO) collapse — breadth-led small/mid rally, not a few names dragging the index

Price Table

Stock Price RSI vs SMA20 7D% 30D% 3M% 52wkHi% Signal
NKTR $60.27 36.5 ↓ -2.9% +7.65% -11.92% -19.70% -44.71% ❌ Don't Buy (06-16, 2d stale)
REGN $614.73 39.1 ↓ -1.1% -0.40% -2.23% -18.89% -25.13% ❌ Don't Buy (06-16, 2d stale)
SRPT $15.78 40.1 ↓ -3.5% -1.99% -7.23% -6.29% -37.68% ❌ Don't Buy (06-16, 2d stale)
GILD $123.76 40.4 ↓ -3.4% -0.51% -4.54% -11.72% -21.32% 🔍 Watch
ALNY $282.72 41.7 ↓ -3.9% -2.25% -3.93% -9.12% -43.88% ❌ Don't Buy (06-17)
IQV $170.67 42.6 -4.1% -6.56% -1.45% +2.52% -32.09% ❌ Don't Buy (06-17)
ABBV $216.49 48.1 -1.6% -2.70% +1.28% +5.85% -11.57% 🔍 Watch
EDIT $2.69 48.4 -4.6% +2.68% +9.35% +14.47% -40.71% 🔍 Watch
INCY $98.99 48.2 -0.8% -5.30% +3.55% +6.50% -12.53% 🔍 Watch (06-17)
IONS $74.31 49.6 -0.6% +0.94% +0.64% +4.19% -14.55% 🔍 Watch (06-17)
DXCM $71.23 50.3 -3.0% -2.86% +6.39% +5.89% -19.46% 🔍 Watch (06-17)
NVO $43.55 50.6 -0.5% +5.75% -1.65% +17.48% -42.53% 🔍 Watch (06-16, 2d stale)
BMRN $55.02 50.7 +0.2% -2.15% +10.46% -0.02% -17.49% 🔍 Watch (06-17)
BNTX $92.22 52.9 +2.1% -0.72% +5.05% +3.26% -26.70% 🔍 Watch (06-17)
LABU $184.63 53.4 +5.5% +13.55% +14.95% +17.25% -13.09% 🔍 Watch (06-16, 2d stale)
ILMN $159.09 54.1 +0.2% -0.98% +12.29% +25.67% -8.63% 📈 Accumulate (06-17)
CRSP $54.09 55.1 +3.1% +4.18% +13.66% +15.21% -31.08% 🔍 Watch
BIIB $198.67 55.2 +1.9% -0.78% +4.26% +8.32% -4.56% 🔒 Hold (06-17)
RARE $24.85 56.5 +6.9% +12.70% +2.73% +15.05% -41.35% 🔍 Watch (06-16, 2d stale)
IBBQ $29.94 56.5 +2.0% +0.98% +5.24% +6.02% -1.70% 🔒 Hold (06-17)
COGT $34.54 56.6 +4.3% +2.80% +10.53% -0.20% -21.02% 🔍 Watch
NTLA $14.55 56.6 +10.4% +11.00% +14.66% +7.94% -48.50% 🔍 Watch (06-16, 2d stale)
LEGN $33.38 56.7 +5.7% +10.52% +23.72% +79.95% -26.31% 📈 Accumulate (06-16, 2d stale)
IBB $173.64 57.2 +2.3% +1.23% +5.77% +5.59% -3.34% 🔒 Hold
VRTX $453.17 58.6 +3.0% +1.56% +3.80% -2.02% -10.78% 🔒 Hold (06-16, 2d stale)
DNA $9.17 59.0 +6.9% +12.27% +24.59% +32.71% -47.84% 🔍 Watch
LLY $1,098.57 60.3 -0.1% -2.63% +7.55% +20.86% -7.12% 🔒 Hold
PTGX $110.64 61.1 +8.5% +13.59% +9.83% +13.79% -2.66% 📈 Accumulate (06-16, 2d stale)
BEAM $34.14 61.9 +11.5% +11.33% +29.66% +35.64% -6.31% 📈 Accumulate
XBI $140.72 62.2 +5.6% +3.69% +5.98% +15.03% -2.77% 🔒 Hold
KYMR $87.44 63.0 +10.2% +15.74% +9.75% +7.67% -15.11% 📈 Accumulate (06-16, 2d stale)
MRNA $55.40 64.4 +14.8% +10.58% +15.15% +2.73% -6.97% 📈 Accumulate (06-16, 2d stale)

Tier Analysis

Oversold / Collapsing (RSI < 45)

  • NKTR ($60.27, RSI 37) — Nektar: collapse regime, -19.7% 3M, -45% from ATH. Despite +7.65% 7D bounce and golden cross, RSI is the weakest in the scan. Wait for trend confirmation. (06-16, 2d stale)
  • REGN ($614.73, RSI 39) — Regeneron: strong-down, death-cross, -18.9% 3M. Antibody franchise re-rating; -25% from ATH. No entry. (06-16, 2d stale)
  • SRPT ($15.78, RSI 40) — Sarepta: downtrend, death-cross, -38% from ATH. Gene-therapy gene-therapy safety overhang; structural decline. (06-16, 2d stale)
  • GILD ($123.76, RSI 40) — Gilead: pullback, -11.7% 3M, -21% from ATH. Golden cross still intact; watch for RSI < 40 capitulation entry.
  • ALNY ($282.72, RSI 42) — Alnylam: collapse regime, -43.9% from ATH, death-cross. RNAi platform leader in deep drawdown; no reversal signal. (06-17)

Neutral / Basing (RSI 45–60)

  • ABBV ($216.49, RSI 48) — AbbVie: basing, +5.85% 3M, -11.6% from ATH. Death-cross but holding above SMA50. Stable large-cap.
  • BIIB ($198.67, RSI 55) — Biogen: strong-up, golden cross, +13.9% vs SMA200, -4.6% from ATH. Alzheimer's franchise re-rating. Hold. (06-17)
  • ILMN ($159.09, RSI 54) — Illumina: uptrend, +25.7% 3M, golden cross, +25.9% vs SMA200. Sequencing recovery; -8.6% from ATH. Best large-cap momentum. (06-17)
  • CRSP ($54.09, RSI 55) — CRISPR Tx: +13.7% 30D, +15.2% 3M; gene-editing cohort participation. Death-cross still but price reclaiming SMA20/50. (06-18)
  • VRTX ($453.17, RSI 59) — Vertex: basing, +3.8% 30D, -10.8% from ATH. CF franchise + pipeline. Hold. (06-16, 2d stale)
  • DNA ($9.17, RSI 59) — Ginkgo Bioworks: +24.6% 30D, +32.7% 3M speculative ripper; still -47.8% from ATH and death-cross. High-beta spec name.

Momentum / Leading (RSI 60–65)

  • LLY ($1,098.57, RSI 60) — Eli Lilly: GLP-1 oligopoly anchor, +20.9% 3M, golden cross, -7% from ATH. The sector's premier compounder. Hold.
  • PTGX ($110.64, RSI 61) — Protagonist: +13.6% 7D, near ATH (-2.7%), golden cross, +27% vs SMA200. Strong momentum, +107% 1Y. (06-16, 2d stale)
  • BEAM ($34.14, RSI 62) — Beam Therapeutics: base-editing leader, +29.7% 30D, +35.6% 3M, golden cross, -6.3% from ATH, +103.7% 1Y. Lead gene-editing momentum name.
  • XBI ($140.72, RSI 62) — SPDR Biotech ETF: breakout regime, golden cross, +15% 3M, -2.8% from ATH. The cleanest expression of the broad small/mid biotech risk-on.
  • KYMR ($87.44, RSI 63) — Kymera: +15.7% 7D, +19.7% vs SMA200, golden cross, +90.6% 1Y. Targeted-protein-degradation momentum. (06-16, 2d stale)
  • MRNA ($55.40, RSI 64) — Moderna: mRNA platform re-rating, +10.6% 7D, +15.2% 30D, +42.7% vs SMA200, golden cross, +113.9% 1Y. Confirmed across both biotech + healthcare scans. (06-16, 2d stale)

Entry Zones

Stock Price Zone RSI 30D% Setup
MRNA $55.40 <$58 64.4 +15.2% mRNA re-rating; +42.7% vs SMA200; momentum early innings; GC
BEAM $34.14 <$33 61.9 +29.7% Base-editing leader; -6.3% from ATH; GC; pullback to SMA20 = entry
ILMN $159.09 <$155 54.1 +12.3% Sequencing recovery; +25.7% 3M; -8.6% from ATH; cleanest large-cap
LEGN $33.38 <$32 56.7 +23.7% +80% 3M ripper; CAR-T; +29.6% vs SMA200; wait for consolidation
GILD $123.76 <$120 40.4 -4.5% HIV antivirals; -21% from ATH; GC intact; watch RSI < 40 capitulation

Action Matrix

Action Stocks Why
🔒 HOLD XBI, IBB, IBBQ, LLY, BIIB, VRTX ETFs golden-crossed near ATH; large-cap anchors with intact theses
📈 ACCUMULATE MRNA, BEAM, KYMR, LEGN, PTGX, ILMN Strong-up + golden cross + momentum confirmation across gene-edit / mRNA / TPD cohort
🔍 WATCH CRSP, NTLA, EDIT, DNA, COGT, RARE, BMRN, INCY, IONS, BNTX, LABU, ABBV, GILD, NVO, DXCM Participating in the rally but death-cross or extended drawdown — wait for trend confirmation
❌ DON'T BUY NKTR, REGN, SRPT, ALNY, IQV Collapse / strong-down regimes; RSI < 43; structural declines not finished

What Changed

  • XBI broke out — SPDR Biotech ETF now in breakout regime (RSI 62, -2.8% from ATH) with golden cross. The ETF complex (IBB/IBBQ/LABU) all golden-crossed = breadth-led rally, not a narrow few.
  • Gene-editing cohort ripping — BEAM (+29.7% 30D), CRSP (+13.7% 30D), NTLA (+14.7% 30D), EDIT (+9.4% 30D) all up together. BEAM the clear leader (golden cross, near ATH).
  • LEGN +80% 3M — Legend Biotech the single biggest 3M mover in the scan; CAR-T (carvykti) franchise re-rate, +29.6% vs SMA200. (06-16, 2d stale)
  • MRNA confirmed dual-scan — mRNA re-rating shows up in both biotech and healthcare scans; +113.9% 1Y, +42.7% vs SMA200. Most significant platform inflection.
  • Large-cap antibody/RNAi divergence — REGN (-18.9% 3M), ALNY (-43.9% from ATH), NVO (-42.5% from ATH) all in death-cross while small/mid-caps rip. Risk appetite skipping the majors.
  • KYMR / PTGX momentum — Targeted-protein-degradation (KYMR +15.7% 7D) and Protagonist (PTGX near ATH) both leading; the rally is platform-tech-led.

Key Discoveries

Discovery Implication
XBI/IBB/IBBQ/LABU all golden-crossed simultaneously Breadth-led small/mid biotech risk-on, not index dragged by a few names
Gene-editing (BEAM/CRSP/NTLA/EDIT) up as a cohort Sector-wide rotation into platform biotech, confirmation not noise
Large-cap antibody/RNAi (REGN/ALNY) collapse while ETFs near ATH The rally is bypassing legacy majors — small/mid is where the risk appetite is

Mistakes (Don't Repeat)

Mistake Lesson
Treating REGN/ALNY weakness as a sector tell The ETFs broke out — large-cap divergence is rotation, not sector breakdown
Chasing NKTR on the +7.65% 7D bounce RSI 37 + collapse regime; a one-week bounce inside a downtrend is not a trend (06-16 stale data adds caution)

Open Questions

  • Is the XBI breakout the start of a durable small/mid biotech bull, or a risk-on spike to fade?
  • LEGN +80% 3M: how much of the CAR-T re-rate is left, or is it now extended? (data is 06-16, 2d stale)
  • Do the large-cap laggards (REGN/ALNY/GILD) eventually catch the bid, or is the divergence structural?
10 events
DateTypeEvent
Jun 16 ScanBiotech Scan Jun 26 ScanBiotech Scan Jul 7 ScanBiotech Scan Jul 11 ScanBiotech Scan May 29 ScanBiotech Scan Jul 17 ScanBiotech Scan Jun 25 ScanBiotech Scan Jul 25 ScanBiotech Scan Jul 28 ScanBiotech Scan Jul 31 ScanBiotech Scan

No direct external sources are attached to this read.